The above article, published online on 7 February 2005, in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the journal Editor-in-Chief, Prof. Peter Lichter, the Union for International Cancer Control and John Wiley & Sons, Ltd. The retraction has been agreed due to reuse of several figure panels in the paper. Due to the time elapsed since the publication of the article, the original data for these figures are no longer available for re-analysis. The authors are therefore not able to confirm the accuracy of the reported results or provide updated figures to replace the duplicated panels. Reference International Journal of Cancer Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro Volume 115, Issue 4, 1 July 2005, Pages: 630-640, Claudio Festuccia, Giovanni Luca Gravina, Adriano Angelucci, Danilo Millimaggi, Paola Muzi, Carlo Vicentini and Mauro Bologna Version of Record online : 7 FEB 2005, DOI: 10.1002/ijc.20917.
© 2019 UICC.
Retraction: 'Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells' by Nobuyuki Kikuno, Hiroaki Shiina, Shinji Urakami, Ken Kawamoto, Hiroshi Hirata, Yuichiro Tanaka, Shahana Majid, Mikio Igawa and Rajvir Dahiya.Int J Cancer. 2017 Oct 1;141(7):1492. doi: 10.1002/ijc.30829. Epub 2017 Jun 20. Int J Cancer. 2017. PMID: 28782102
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.Int J Cancer. 2005 Jul 1;115(4):630-40. doi: 10.1002/ijc.20917. Int J Cancer. 2005. PMID: 15700310 Retracted.
Retraction.Int J Cancer. 2019 Aug 15;145(4):1165. doi: 10.1002/ijc.32281. Epub 2019 Mar 29. Int J Cancer. 2019. PMID: 31219630
Retraction.Int J Cancer. 2016 Nov 1;139(9):2145-6. doi: 10.1002/ijc.30269. Int J Cancer. 2016. PMID: 27534917
Retracted: FLT3: beyond good and evil.Hematol Oncol. 2016 Jul 29. doi: 10.1002/hon.2330. Online ahead of print. Hematol Oncol. 2016. PMID: 27468697 Retracted. Review.